Elba Etchebehere1, Ana Emilia Brito1, Alireza Rezaee2, Werner Langsteger2, Mohsen Beheshti3,4. 1. Division of Nuclear Medicine, The University of Campinas, Campinas, Brazil. 2. Department of Nuclear Medicine & Endocrinology, PET - CT Center LINZ, Ordensklinikum, St. Vincent's Hospital, Seilerstaette 4, A-4020, Linz, Austria. 3. Department of Nuclear Medicine & Endocrinology, PET - CT Center LINZ, Ordensklinikum, St. Vincent's Hospital, Seilerstaette 4, A-4020, Linz, Austria. mohsen.beheshti@ordensklinikum.at. 4. Department of Nuclear Medicine & Endocrinology, Paracelsus Medical University, Salzburg, Austria. mohsen.beheshti@ordensklinikum.at.
Abstract
PURPOSE: Defining an optimal imaging modality for assessment of therapy and the best time of evaluation are pivotal for ideal patient's management. METHODS: 223Ra (Xofigo®, formerly Alpharadin) has been approved by the FDA and European Medicines Agency for treatment of metastatic castration-resistant prostate cancer with painful osseous involvement. RESULTS: PET/CT imaging using various radiotracers such as 18F-FDG, 18F-FCH, 68Ga-PSMA and 18F-NaF have been investigated to mitigate the limitations of conventional imaging modalities. Diagnostic radiotracers that have properties similar to a therapeutic radiotracer will precisely assess of the possibility and efficacy of a treatment; this is the theranostic concept. An example of a diagnostic test employed for selecting targeted therapy is the combined use of 18F-fluoride PET/CT for evaluation of possible therapy with 223Ra. CONCLUSION: This review examines the most recent publications related to this topic.
PURPOSE: Defining an optimal imaging modality for assessment of therapy and the best time of evaluation are pivotal for ideal patient's management. METHODS: 223Ra (Xofigo®, formerly Alpharadin) has been approved by the FDA and European Medicines Agency for treatment of metastatic castration-resistant prostate cancer with painful osseous involvement. RESULTS: PET/CT imaging using various radiotracers such as 18F-FDG, 18F-FCH, 68Ga-PSMA and 18F-NaF have been investigated to mitigate the limitations of conventional imaging modalities. Diagnostic radiotracers that have properties similar to a therapeutic radiotracer will precisely assess of the possibility and efficacy of a treatment; this is the theranostic concept. An example of a diagnostic test employed for selecting targeted therapy is the combined use of 18F-fluoride PET/CT for evaluation of possible therapy with 223Ra. CONCLUSION: This review examines the most recent publications related to this topic.
Entities:
Keywords:
223Ra; Bone metastasis; Prostate cancer; Therapy monitoring
Authors: Karen A Kurdziel; Joanna H Shih; Andrea B Apolo; Liza Lindenberg; Esther Mena; Yolanda Y McKinney; Stephen S Adler; Baris Turkbey; William Dahut; James L Gulley; Ravi A Madan; Ola Landgren; Peter L Choyke Journal: J Nucl Med Date: 2012-06-22 Impact factor: 10.057
Authors: Saima Muzahir; Robert Jeraj; Glenn Liu; Lance T Hall; Alejandro Munoz Del Rio; Timothy Perk; Christine Jaskowiak; Scott B Perlman Journal: Am J Nucl Med Mol Imaging Date: 2015-01-15
Authors: C Schiepers; J Nuyts; G Bormans; J Dequeker; R Bouillon; L Mortelmans; A Verbruggen; M De Roo Journal: J Nucl Med Date: 1997-12 Impact factor: 10.057
Authors: Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Josef Hammer; Wolfgang Loidl; Christian Pirich; Ignac Fogelman; Werner Langsteger Journal: Mol Imaging Biol Date: 2009 Nov-Dec Impact factor: 3.488
Authors: Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger Journal: Eur J Nucl Med Mol Imaging Date: 2008-05-09 Impact factor: 9.236